Key Stats
- Moderna expected 2025 revenue range of $1.5 to $2.2 billion with majority concentrated in second half of year
- Cash and investments position of $8.4 billion as of March 31, 2025
- Market capitalization approximately $10.44 billion as of October 2025
- Company advancing up to 10 products toward approval including multiple oncology candidates
- Moderna RSV vaccine approved in approximately 40 countries with FDA approval for expanded age group 18-59
Moderna Inc is an American pharmaceutical and biotechnology company headquartered in Cambridge, Massachusetts. The company focuses on developing messenger RNA-based vaccines and therapeutics across infectious diseases, oncology, rare diseases, and autoimmune conditions.
Founded in 2010, Moderna pioneered the mRNA medicine field and gained global recognition for developing one of the first COVID-19 vaccines authorized for emergency use. The company operates manufacturing facilities in Massachusetts and maintains a robust clinical pipeline with 44 treatment and vaccine candidates.
The biotechnology firm generates revenue primarily through product sales of Spikevax COVID-19 vaccine and mRESVIA RSV vaccine. Moderna continues to invest heavily in research and development while implementing cost reduction strategies to achieve operational efficiency and sustainable growth.
Moderna Inc History
Moderna was founded in September as ModeRNA Therapeutics by Noubar Afeyan, Robert Langer, Kenneth Chien, Derrick Rossi, and Timothy Springer. The company was established to commercialize Rossi’s breakthrough research on using modified mRNA to reprogram cells.
Stéphane Bancel joined as CEO, bringing leadership that would guide the company through its transformation. The research team demonstrated first proof of concept for engineered mRNA in laboratory settings.
Moderna formed a five-year exclusive partnership with AstraZeneca to develop mRNA treatments for cardiovascular, metabolic, and renal diseases. The company also received a $25 million DARPA grant through the ADEPT-PROTECT program.
The company rebranded from ModeRNA Therapeutics to Moderna Inc and completed its initial public offering in December, raising $600 million in what was then the largest biotech IPO in history.
Moderna developed mRNA-1273 COVID-19 vaccine in partnership with the National Institute of Allergy and Infectious Diseases and BARDA. The vaccine received emergency use authorization in December 2020.
The FDA granted full approval for Spikevax COVID-19 vaccine for individuals 18 and older in January. Moderna announced plans to build a $180 million vaccine manufacturing facility in Montreal, Canada.
Moderna completed its first acquisition, purchasing OriCiro Genomics for $85 million to enhance DNA synthesis capabilities for mRNA production. The company also settled patent disputes with NIH, Dartmouth, and Scripps Research for $400 million.
The FDA approved mRESVIA respiratory syncytial virus vaccine for adults 60 and older in May. Moderna expanded research collaborations including a partnership with Merck on cancer immunotherapy candidate mRNA-4157.
The FDA approved expanded indication for mRESVIA vaccine to include adults 18-59 at increased risk for RSV. Moderna announced cost reduction initiatives targeting $1.5 billion in operational expense savings by 2027.
Moderna Inc Co-founders
Noubar Afeyan
Venture capitalist and biochemical engineer who founded Flagship Pioneering. Afeyan recognized the revolutionary potential of engineered mRNA as a new class of medicine and served as the driving force behind Moderna’s creation, currently serving as Chairman of the Board.
Robert Langer
Renowned MIT professor and bioengineering pioneer with over 1,000 scientific papers and 800 patents. Langer’s expertise in drug delivery systems and biomaterials proved instrumental in developing Moderna’s mRNA platform technology and continues to serve as a company director.
Derrick Rossi
Canadian stem cell biologist whose 2009 breakthrough using modified mRNA to reprogram adult cells into induced pluripotent stem cells became the scientific foundation for Moderna. Rossi left the company in 2014 after establishing its core technology.
Kenneth Chien
Cardiovascular researcher and cardiologist who recognized the therapeutic potential of mRNA technology. Chien contributed his medical expertise to help translate the basic science into potential clinical applications during company formation.
Timothy Springer
Harvard Medical School immunologist and successful biotech entrepreneur who connected Rossi with venture capital resources. Springer facilitated the initial meetings that led to Moderna’s founding and helped secure early funding through his network.
Moderna Inc Market Cap
Moderna Inc market capitalization stands at approximately $10.44 billion as of October 2025. The company’s valuation decreased from peak levels during the COVID-19 pandemic as vaccine revenues normalized into seasonal respiratory product market.
Moderna Inc Revenue
Moderna projects 2025 revenue between $1.5 and $2.2 billion, primarily from Spikevax and mRESVIA vaccine sales. The company experienced significant revenue growth during the pandemic years before transitioning to seasonal respiratory business model.
Moderna Inc Acquisitions
Moderna completed its first strategic acquisition in January 2023, purchasing OriCiro Genomics for $85 million. The Japanese company specializes in cell-free synthesis and amplification of plasmid DNA, a critical component in mRNA manufacturing processes.
The acquisition provided Moderna with proprietary technology for faster DNA production without traditional bacterial cloning methods. OriCiro’s platform enables accelerated research and development timelines by improving synthesis speed and reducing purification requirements. This strategic move aligned with CEO Stéphane Bancel’s stated focus on expanding nucleic acid capabilities rather than pursuing large acquisitions.
Beyond outright acquisitions, Moderna has pursued extensive licensing partnerships and research collaborations. The company entered a major collaboration with German biotechnology firm Immatics in September 2023, agreeing to pay up to $1.8 billion including $120 million upfront for joint cancer therapy development. This partnership combines Moderna’s mRNA technology with Immatics’ immunotherapy platforms.
Moderna maintains a 50-50 partnership with Merck on individualized neoantigen therapy mRNA-4157, with Merck having paid $250 million in 2022 to exercise its option. The companies jointly develop and share costs for this promising cancer immunotherapy candidate. Moderna has also established collaborations with AstraZeneca, Vertex Pharmaceuticals, and numerous academic institutions to advance its therapeutic pipeline.
The company’s acquisition strategy emphasizes technology platforms and manufacturing capabilities over large pharmaceutical mergers. Moderna executives have repeatedly stated their intention to remain focused on mRNA medicine leadership rather than diversifying through major deals. This approach reflects confidence in the broad applicability of mRNA technology across multiple disease areas.
While Moderna’s acquisition activity has been limited compared to traditional pharmaceutical companies, industry observers anticipate potential future deals as the company seeks to expand beyond vaccines into therapeutics. The substantial cash reserves provide flexibility for strategic transactions that enhance platform capabilities or accelerate pipeline development across infectious diseases, oncology, and rare disease programs.
Moderna Inc Competitors
Moderna competes in the mRNA therapeutics and vaccine space against pharmaceutical and biotechnology companies pursuing similar technologies. Primary competitors include BioNTech and Pfizer in mRNA vaccines and broader pharmaceutical rivals in respiratory and oncology markets.
| Company | Primary Focus | Notable Products |
|---|---|---|
| Pfizer / BioNTech | mRNA vaccines, pharmaceuticals | Comirnaty COVID-19 vaccine |
| Novavax | Protein-based vaccines | Nuvaxovid COVID-19 vaccine |
| GSK | Vaccines, pharmaceuticals | Arexvy RSV vaccine |
| Johnson & Johnson | Pharmaceuticals, vaccines | COVID-19 vaccine, oncology |
| AstraZeneca | Biopharmaceuticals | Vaxzevria COVID-19 vaccine |
| Sanofi | Vaccines, specialty care | Influenza vaccines |
| Regeneron | Biotechnology | Monoclonal antibodies |
| CureVac | mRNA therapeutics | mRNA vaccine development |
| Translate Bio | mRNA therapeutics | Rare disease treatments |
| Merck | Pharmaceuticals, vaccines | Keytruda, vaccines |
FAQs
What does Moderna Inc specialize in producing?
Moderna specializes in messenger RNA-based medicines and vaccines for infectious diseases, oncology, rare diseases, and autoimmune conditions. The company’s commercial products include Spikevax COVID-19 vaccine and mRESVIA respiratory syncytial virus vaccine for adults.
When was Moderna Inc founded and by whom?
Moderna was founded in September 2010 by Noubar Afeyan, Robert Langer, Derrick Rossi, Kenneth Chien, and Timothy Springer. The company was established to commercialize Rossi’s breakthrough research using modified mRNA to reprogram cells into stem cells.
Where is Moderna Inc headquarters located?
Moderna Inc maintains its headquarters in Cambridge, Massachusetts, United States. The company operates manufacturing facilities in Massachusetts and has established international collaborations and partnerships for vaccine production and distribution globally.
How much revenue does Moderna Inc generate annually?
Moderna expects to generate between $1.5 and $2.2 billion in revenue for 2025. The company generated $3.24 billion in 2024, down from $6.85 billion in 2023 and $19.26 billion in 2022 during peak COVID-19 vaccine demand.
What is Moderna Inc current market capitalization?
Moderna Inc has a market capitalization of approximately $10.44 billion as of October 2025. The company’s valuation declined significantly from pandemic peaks as COVID-19 vaccine sales transitioned to seasonal respiratory market with reduced demand.